As demonstrated by others, the binding capacity of albumin is diminished in CKD patients, most likely due to posttranslational modifications of albumin sites which could contribute to less efficient transport of uremic toxins by the renal tubular excretory machinery [70,71,72], thus resulting in further elevated plasma levels and their well-known consequences. This evidence concerns the gene ALB and chronic kidney disease.